Laura Fusar-Poli1, Andrea Amerio2,3,4, Patriciu Cimpoesu2,3, Antimo Natale1, Virginio Salvi5, Guendalina Zappa2,3, Gianluca Serafini2,3, Mario Amore2,3, Eugenio Aguglia1, Andrea Aguglia2,3. 1. Department of Clinical and Experimental Medicine, Psychiatry Unit, University of Catania, 95123 Catania, Italy. 2. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Section of Psychiatry, University of Genoa, 16123 Genoa, Italy. 3. IRCCS Ospedale Policlinico San Martino, 16123 Genoa, Italy. 4. Department of Psychiatry, Tufts University, Boston, MA 02111, USA. 5. Department of Clinical Neurosciences, Polytechnic University of Marche, 60121 Ancona, Italy.
Abstract
Background and Objectives: Bipolar disorder (BD) is a severe mental condition with a lifetime prevalence estimated around 2% among the general population. Due to risk factors, etiological mechanisms, and the chronic use of psychotropic medications, people with BD are frequently affected by medical comorbidities, such as metabolic syndrome (MetS), associated with altered blood levels of glucose, cholesterol, and triglycerides. Moreover, the lipid concentration may be associated with the severity of psychiatric symptoms. Materials and Methods: Five hundred and forty-two in- and outpatients (418 affected by BD and 124 affected by schizophrenia) were recruited in two Italian university hospitals. A blood examination assessing the fasting glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides was performed. Results: No significant differences were found in the lipid and glycemic profiles between patients with BD and schizophrenia. When considering only the BD sample, we found that patients experiencing a manic episode had significantly lower total cholesterol, HDL, and LDL than euthymic patients. Moreover, the total and LDL cholesterol levels were significantly lower in (hypo)manic than depressed patients. Mood episodes did not influence the triglyceride and glucose levels in our sample. Conclusions: Clinicians should pay attention to blood cholesterol levels in patients with BD, as differences in concentrations may predispose them to severe medical conditions and can be associated with the onset of mood episodes.
Background and Objectives:Bipolar disorder (BD) is a severe mental condition with a lifetime prevalence estimated around 2% among the general population. Due to risk factors, etiological mechanisms, and the chronic use of psychotropic medications, people with BD are frequently affected by medical comorbidities, such as metabolic syndrome (MetS), associated with altered blood levels of glucose, cholesterol, and triglycerides. Moreover, the lipid concentration may be associated with the severity of psychiatric symptoms. Materials and Methods: Five hundred and forty-two in- and outpatients (418 affected by BD and 124 affected by schizophrenia) were recruited in two Italian university hospitals. A blood examination assessing the fasting glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides was performed. Results: No significant differences were found in the lipid and glycemic profiles between patients with BD and schizophrenia. When considering only the BD sample, we found that patients experiencing a manic episode had significantly lower total cholesterol, HDL, and LDL than euthymic patients. Moreover, the total and LDL cholesterol levels were significantly lower in (hypo)manic than depressedpatients. Mood episodes did not influence the triglyceride and glucose levels in our sample. Conclusions: Clinicians should pay attention to blood cholesterol levels in patients with BD, as differences in concentrations may predispose them to severe medical conditions and can be associated with the onset of mood episodes.
Authors: Joseph Firth; Najma Siddiqi; Ai Koyanagi; Dan Siskind; Simon Rosenbaum; Cherrie Galletly; Stephanie Allan; Constanza Caneo; Rebekah Carney; Andre F Carvalho; Mary Lou Chatterton; Christoph U Correll; Jackie Curtis; Fiona Gaughran; Adrian Heald; Erin Hoare; Sarah E Jackson; Steve Kisely; Karina Lovell; Mario Maj; Patrick D McGorry; Cathrine Mihalopoulos; Hannah Myles; Brian O'Donoghue; Toby Pillinger; Jerome Sarris; Felipe B Schuch; David Shiers; Lee Smith; Marco Solmi; Shuichi Suetani; Johanna Taylor; Scott B Teasdale; Graham Thornicroft; John Torous; Tim Usherwood; Davy Vancampfort; Nicola Veronese; Philip B Ward; Alison R Yung; Eoin Killackey; Brendon Stubbs Journal: Lancet Psychiatry Date: 2019-07-16 Impact factor: 27.083
Authors: Davy Vancampfort; Kristof Vansteelandt; Christoph U Correll; Alex J Mitchell; Amber De Herdt; Pascal Sienaert; Michel Probst; Marc De Hert Journal: Am J Psychiatry Date: 2013-03 Impact factor: 18.112
Authors: Joseph F Hayes; Louise Marston; Kate Walters; John R Geddes; Michael King; David P J Osborn Journal: PLoS Med Date: 2016-08-02 Impact factor: 11.069
Authors: Antimo Natale; Carmen Concerto; Alessandro Rodolico; Andrea Birgillito; Marina Bonelli; Miriam Martinez; Maria Salvina Signorelli; Antonino Petralia; Carmenrita Infortuna; Fortunato Battaglia; Eugenio Aguglia Journal: Int J Environ Res Public Health Date: 2022-02-24 Impact factor: 3.390